Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Hangzhou Zhongmei Huadong Pharmaceutical

Pharmaceutical intelligence for Hangzhou Zhongmei Huadong Pharmaceutical with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
0
Assets
1

Recent signals(1)

ClinicalJune 24, 2026

Phase III Trial of MC2-01 Cream for Plaque Psoriasis Shows Efficacy and Safety

A Phase III trial is underway to evaluate the efficacy and safety of MC2-01 cream compared to existing treatments in plaque psoriasis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJune 24, 2026

Phase III Trial of MC2-01 Cream for Plaque Psoriasis Shows Efficacy and Safety

A Phase III trial is underway to evaluate the efficacy and safety of MC2-01 cream compared to existing treatments in plaque psoriasis.

Competitive activity

No signals indexed for this entity yet.

Assets

Phase →

Therapeutic areas

Dermatology →
Psoriasis →

Indications

Psoriasis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.